Table 1

Correlation between Akt2, p-Akta, p-ERK 1/2a, and Ki-67 expression and clinicopathological factors in 61 patients with pancreatic ductal adenocarcinoma

FactorsCategoryTotal no. of patientsPatients with high-intensity Akt2 (n = 26)PPatients with high-intensity p-Akt (n = 28)PPatients with high-intensity p-ERK 1/2 (n = 39)PPatients with level 2 Ki-67 LI (n = 46)P
Age (years)1: ≤60156 (40.0%)N.S.7 (46.7%)N.S.9 (60.0%)N.S.10 (66.7%)N.S.
2: >604620 (43.5%)21 (45.7%)30 (65.2%)36 (78.3%)
Gender1: Male3413 (38.2%)N.S.12 (35.3%)N.S.20 (58.8%)N.S.28 (82.4%)N.S.
2: Female2713 (48.1%)16 (59.3%)19 (70.4%)18 (66.7%)
Location of tumor1: Head5023 (46.0%)N.S.24 (48.0%)N.S.31 (62.0%)N.S.36 (72.0%)N.S.
2: Body/Tail113 (27.3%)4 (36.4%)8 (72.7%)10 (90.9%)
T (pTNM)1: T141 (25.0%)N.S.1 (25.0%)N.S.2 (50.0%)N.S.3 (75.0%)N.S.
2: T273 (42.9%)3 (42.9%)5 (71.4%)3 (42.9%)
3: T33113 (41.9%)15 (48.4%)20 (64.5%)23 (74.2%)
4: T4199 (52.6%)9 (52.6%)12 (63.2%)17 (89.5%)
Histological differentiation1: Well2913 (44.8%)N.S.14 (48.3%)N.S.19 (65.5%)N.S.25 (86.2%)N.S.
2: Moderately238 (34.8%)11 (47.8%)14 (60.9%)14 (60.9%)
3: Poorly95 (55.6%)3 (33.3%)6 (66.7%)7 (77.8%)
Lymph node metastasis1: Present3615 (41.7%)N.S.17 (47.2%)N.S.24 (66.7%)N.S.28 (77.8%)N.S.
2: Absent2511 (44.0%)11 (44.0%)15 (60.0%)18 (72.0%)
Stage (pTNM)1: I41 (25.0%)N.S.1 (25.0%)N.S.2 (50.0%)N.S.2 (50.0%)N.S.
2: II3816 (42.1%)18 (47.4%)25 (65.8%)27 (71.1%)
3: III199 (47.4%)9 (47.4%)12 (63.2%)17 (89.5%)
Akt2 expression1: Low intensity3511 (31.4%)<0.0121 (60.0%)N.S.25 (71.4%)N.S.
2: High intensity2617 (65.4%)18 (69.2%)21 (80.8%)
p-Akt expression1: Low intensity339 (27.3%)<0.0120 (60.6%)N.S.26 (78.8%)N.S.
2: High intensity2817 (60.7%)19 (67.9%)20 (71.4%)
p-ERK 1/2 expression1: Low intensity228 (36.4%)N.S.9 (40.9%)N.S.16 (34.8%)N.S.
2: High intensity3918 (46.2%)19 (48.7%)30 (76.9%)
Ki-67 LI1: Level 1 (<20%)155 (33.3%)N.S.8 (53.3%)N.S.9 (60.0%)N.S.
2: Level 2 (≥20%)4621 (45.7%)20 (43.5%)30 (65.2%)
  • a p-Akt, phosphorylated Akt; p-ERK 1/2, phosphorylated extracellular signal-regulated kinase 1 and 2; Ki-67 LI, Ki-67 labeling index; N.S., nonsignificant; pTNM, pathological Tumor-Node-Metastasis.